Bisindolylmaleimide VIII facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases

Nature Medicine

Volumn 5, Issue 1, 1999, Pages 42-48

  Zhou, Tong ^a   Song, Ling ^b   Yang, Pingar ^a   Wang, Zheng ^a   Lui, Di ^a   Jope, Richard S ^b  

^a The University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISINDOLYLMALEIMIDE;

ALLERGIC ENCEPHALITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTHRITIS; ARTICLE; ASTROCYTOMA; DRUG EFFECT; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHOCYTE DEPLETION; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; ARTHRITIS, EXPERIMENTAL; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME INHIBITORS; HUMANS; INDOLES; JURKAT CELLS; LYMPHOCYTE ACTIVATION; MALEIMIDES; MICE; MICE, INBRED MRL LPR; PROTEIN KINASE C; RATS; RATS, INBRED LEW; T-LYMPHOCYTES; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033010882     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/4723     Document Type: Article

References (25)

1. Jacobson, M.D., Weil, M. & Raff, M.C. Programmed cell death in animal development. Cell 88, 347-354 (1997).
2. Itoh, N. et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66, 233-243 (1991).
3. Yonehara, S., Ishii, A. & Yonehara, M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med. 169, 1747-1756 (1989).
4. Suda, T., Takahashi, T., Gostein, P. & Nagata, S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75, 1169-1178 (1993).
5. Nagata, S. Apoptosis by death factor. Cell 88, 355-365 (1997).
6. Saas, P. et al. Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain? J. Clin. Invest. 99, 1173-1178 (1997).
7. Weller, M. et al. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. J. Clin. Invest. 94, 954-964 (1994).
8. Watanabe-Fukunaga, R. et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356, 314-317 (1992).
9. Takahashi, T. et al. Generalized lymphoproliferative disease in mice caused by a point mutation in the Fas ligand. Cell 76, 969-976 (1994).
10. Ju, S.T. et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373, 444-448 (1995).
11. Brunner, T. et al. Cell-autonomous Fas(CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373, 441-444 (1995).
12. Dhein, J., Walczak, H., Baumler, C., Debatin, K.M. & Krammer, P.H. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373, 438-441 (1995).
13. Su, X. et al. Defective expression of hematopoietic protein tyrosine phosphatase (HCP) in lymphoid cells blocks Fas-mediated apoptosis. Immunity 2, 353-362 (1995).
14. Miyawaki, T. et al. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J. Immunol. 149, 3753-3758 (1992).
15. Ehl, S. et al. Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo. J. Immunol. 156, 2357-2360 (1996).
16. Toullec, D. et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J. Biol. Chem. 266, 1571-1581 (1991).
17. Bit, R.A. et al. Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction, J. Med. Chem. 36, 21-29 (1993).
18. Jacobson, P.B. et al. Anti-inflammatory properties of Go 6850: a selective inhibitor of protein kinase C. J. Pharmacol. Exp. Therap. 275, 995-1002 (1995).
19. Suen, W.E., Bergman, C.M., Hjelmstrom, P. & Ruddle, N.H. A critical role for lymphotoxin in experimental allergic encephalomyelitis. J. Exp. Med. 186, 1233-1240 (1997).
20. Beltman, J., McCormick, F. & Cook, S.J. The selective protein kinase C inhibitor, Ro-31-8220, inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) expression, induces c-Jun expression, and activates Jun N-terminal kinase. J. Biol. Chem. 271, 27018-27024 (1996).
21. Alessi, D.R. The protein kinase C inhibitors Ro 318220 and GF 109203X are equally potent inhibitors of MAPKAP kinase-1β (Rsk-2) and p70 S6 kinase. FEBS Lett. 402, 121-123 (1997).
22. Yeo, E-J., Provost, J.J. & Exton, J.H. Dissociation of tyrosine phosphorylation and activation of phosphoinositide phospholipase C induced by the protein kinase C inhibitor Ro-31-8220 in Swiss 3T3 cells treated with platelet-derived growth factor. Biochim. Biophys. Acta 1356, 308-320 (1997).
23. McFarland, H.I. et al. Amelioration of autoimmune reactions by antigen-induced apoptosis of T cells. Adv. Exp. Med. Biol. 383, 157-166 (1995).
24. Tabi, Z., McCombe, P.A. & Pender, M.P. Antigen-specific down-regulation of myelin basic protein-reactive T cells during spontaneous recovery from experimental autoimmune encephalomyelitis: further evidence of apoptotic deletion of autoreactive T cells in the central nervous system. Int. Immunol. 7, 967-973 (1995).
25. Sun, D., Qin, Y., Chluba, J., Epplen, J.T. & Wekerle, H.. Suppression of experimentally induced autoimmune encephalomyelitis by cytolytic T cell interactions. Nature 332, 843-845 (1988).